Biocon Biologics Scores EU Nod for Denosumab Biosimilars Vevzuo & Evfraxy

Unknown Apr 02, 2026 900 Views

Biocon Biologics Ltd has secured a major regulatory win with the European Commission granting marketing authorisation for its denosumab biosimilars—Vevzuo and Evfraxy—marking a significant milestone in the company’s global expansion strategy. The approval follows positive recomm...